Drug profile · INN
ropeginterferon alfa-2b
BESREMI
ropeginterferon alfa-2b (BESREMI) is a interferon alpha/beta receptor positive modulator.
EMA: approved Antineoplastic and immunomodulating agents (L03) L03AB15
Patents linked 0
Pipeline programs 1
News articles 1
Drug details — ropeginterferon alfa-2b
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
ropeginterferon alfa-2b (BESREMI) is a interferon alpha/beta receptor positive modulator.
Key facts
INN ropeginterferon alfa-2b
Brand BESREMI
Mechanism Interferon alpha/beta receptor positive modulator
Target Interferon alpha/beta receptor
Therapeutic class Antineoplastic and immunomodulating agents (L03)
ATC code L03AB15
Mechanism of action
Interferon alpha/beta receptor positive modulator
Primary target: Interferon alpha/beta receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ropeginterferon alfa-2b?
ropeginterferon alfa-2b (BESREMI) is a interferon alpha/beta receptor positive modulator.
What is the brand name for ropeginterferon alfa-2b?
BESREMI is a marketed brand name for ropeginterferon alfa-2b. Check FDA Drugs@FDA for the current US label holder and prescribing information.